Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial

MLA

Neoptolemos, John P., et al. “Comparison of Adjuvant Gemcitabine and Capecitabine with Gemcitabine Monotherapy in Patients with Resected Pancreatic Cancer (ESPAC-4): A Multicentre, Open-Label, Randomised, Phase 3 Trial.” The Lancet, vol. 389, no. 10073, Mar. 2017, pp. 1011–24. EBSCOhost, https://doi.org/10.1016/S0140-6736(16)32409-6.

APA

Neoptolemos, J. P., Palmer, D. H., Ghaneh, P., Psarelli, E. E., Valle, J. W., Halloran, C. M., Faluyi, O., O’Reilly, D. A., Cunningham, D., Wadsley, J., Darby, S., Meyer, T., Gillmore, R., Anthoney, A., Lind, P., Glimelius, B., Falk, S., Izbicki, J. R., Middleton, G. W., … Büchler, M. W. (2017). Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. The Lancet, 389(10073), 1011–1024. https://doi.org/10.1016/S0140-6736(16)32409-6

Chicago

Neoptolemos, John P, Daniel H Palmer, Paula Ghaneh, Eftychia E Psarelli, Juan W Valle, Christopher M Halloran, Olusola Faluyi, et al. 2017. “Comparison of Adjuvant Gemcitabine and Capecitabine with Gemcitabine Monotherapy in Patients with Resected Pancreatic Cancer (ESPAC-4): A Multicentre, Open-Label, Randomised, Phase 3 Trial.” The Lancet 389 (10073): 1011–24. doi:10.1016/S0140-6736(16)32409-6.